Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
- Published: January 2012
Atherosclerosis Partnering 2009-2014 provides understanding and access to the atherosclerosis partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides an analysis of atherosclerosis partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors atherosclerosis technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
This data driven report contains over 25 links to online copies of actual atherosclerosis deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of atherosclerosis partnering trends.
Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in atherosclerosis partnering since 2009, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.
Chapter 3 provides an overview of the leading atherosclerosis deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive directory of atherosclerosis partnering deals signed and announced since 2009. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the
research, development and commercialization of atherosclerosis technologies and products.
Atherosclerosis Partnering 2009-2014 is intended to provide the reader with an in-depth understanding and access to atherosclerosis trends and structure of deals entered into by leading companies worldwide.
This data driven report includes:
Trends in atherosclerosis dealmaking in the biopharma industry since 2009
Access to summary headline, upfront, milestone and royalty data
Access to over 25 atherosclerosis contract documents
The leading atherosclerosis deals by value since 2009
In Atherosclerosis Partnering 2009-2014, the available deals are listed by:
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. SHOW LESS READ MORE >
Chapter 1 – Introduction
Chapter 2 – Trends in atherosclerosis partnering
2.2. Atherosclerosis partnering over the years
2.3. Bigpharma atherosclerosis dealmaking activity
2.4. Atherosclerosis partnering by deal type
2.5. Atherosclerosis partnering industry sector
2.6. Atherosclerosis partnering by stage of development
2.7. Atherosclerosis partnering by technology type
2.8. Disclosed financial deal terms for atherosclerosis partnering
2.8.1 Atherosclerosis headline values
2.8.2 Atherosclerosis upfront payments
2.8.3 Atherosclerosis milestone payments
2.8.4 Atherosclerosis royalty rates
Chapter 3 – Leading atherosclerosis deals
3.2. Top atherosclerosis deals by value
3.3. Top atherosclerosis deals involving bigpharma
Chapter 4 – Dealmaking directory
4.2. Company A-Z
4.3. By deal type
4.4. By industry sector
4.5. By stage of development
4.6. By technology type
Diagnostic - companion
In vitro models
Chapter 5 – Partnering resource center
5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking
Appendix 1 – Deal type definitions
About Wildwood Ventures
Recent titles from CurrentPartnering
Order Form – Reports
Table of figures
Figure 1: Atherosclerosis partnering since 2009
Figure 2: Bigpharma – top 50 – atherosclerosis deals 2009 to 2011
Figure 3: Bigpharma atherosclerosis deal frequency – 2009 to 2011
Figure 4: Atherosclerosis partnering by deal type since 2009
Figure 5: Atherosclerosis partnering by industry sector since 2009
Figure 6: Atherosclerosis partnering by stage of development since 2009
Figure 7: Atherosclerosis partnering by technology type since 2009
Figure 8: Atherosclerosis deals with a headline value
Figure 9: Atherosclerosis deals with upfront payment values
Figure 10: Atherosclerosis deals with milestone payments
Figure 11: Atherosclerosis deals with royalty rates, %
Figure 12: Top atherosclerosis deals by value since 2009
Figure 13: Top atherosclerosis deals signed by bigpharma value since 2009
Figure 14: Online partnering resources
Figure 15: Forthcoming partnering events
Figure 16: Deal type definitions
Johnson & Johnson
Kyowa Hakko Kirin
Merck & Co